心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2021 ACC/AHA/SCAI指南：冠状动脉血运重建

2021-12-09 美国心脏病学会 Circulation

冠状动脉血运重建

2021年12月，美国心脏病学会(ACC)联合美国心脏协会(AHA)、美国心血管造影和介入学会(SCAI)共同发布了冠状动脉血运重建指南。

中文标题：

2021 ACC/AHA/SCAI指南：冠状动脉血运重建

英文标题：

2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

发布机构：

美国心脏病学会

发布日期：

2021-12-09

简要介绍：

2021年12月，美国心脏病学会(ACC)联合美国心脏协会(AHA)、美国心血管造影和介入学会(SCAI)共同发布了冠状动脉血运重建指南。本文取代了2011年冠状动脉移植术以及2011和2015年经皮冠脉介入治疗指南。文章提出以患者为中心的方法，为冠状动脉血运重建治疗提供指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 ACC_AHA_SCAI指南：冠状动脉血运重建.pdf)] GetToolGuiderByIdResponse(projectId=1, id=de75e1c002288a10, title=2021 ACC/AHA/SCAI指南：冠状动脉血运重建, enTitle=2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, guiderFrom=Circulation, authorId=0, author=, summary=2021年12月，美国心脏病学会(ACC)联合美国心脏协会(AHA)、美国心血管造影和介入学会(SCAI)共同发布了冠状动脉血运重建指南。, cover=https://img.medsci.cn/20211210/1639125703093_1608702.png, journalId=0, articlesId=null, associationId=849, associationName=美国心脏病学会, associationIntro=null, copyright=0, guiderPublishedTime=Thu Dec 09 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年12月，美国心脏病学会(ACC)联合美国心脏协会(AHA)、美国心血管造影和介入学会(SCAI)共同发布了冠状动脉血运重建指南。本文取代了2011年冠状动脉移植术以及2011和2015年经皮冠脉介入治疗指南。文章提出以患者为中心的方法，为冠状动脉血运重建治疗提供指导建议。</span></p>, tagList=[TagDto(tagId=88375, tagName=冠状动脉血运重建)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=43, categoryName=冠心病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=88375, guiderKeyword=冠状动脉血运重建, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8582, appHits=354, showAppHits=0, pcHits=1976, showPcHits=8228, likes=2, shares=55, comments=14, approvalStatus=1, publishedTime=Fri Dec 10 16:47:09 CST 2021, publishedTimeString=2021-12-09, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Fri Dec 10 16:47:00 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 14:58:36 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ACC_AHA_SCAI指南：冠状动脉血运重建.pdf)])
2021 ACC_AHA_SCAI指南：冠状动脉血运重建.pdf
下载请点击：
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1778672, encodeId=b1bd1e786722d, content=紧跟国际发展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2c65414596, createdName=ms6000000101327915, createdTime=Sun Sep 18 22:30:52 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206597, encodeId=faaf120659e04, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Mon Mar 28 11:34:15 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205894, encodeId=7277120589498, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210201/f9ebd76673be43709bf11ecf3e05d29a/4ceebf8544374796ac74a7ce757d6c8f.jpg, createdBy=28e01512509, createdName=40386, createdTime=Fri Mar 25 17:09:43 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181821, encodeId=c0aa11818219c, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXfB3bOYOsDt885AsrYWhiaRtRdPh9aZlXugm7XErBVXusv5fJLIKWTicmjSQcOibDiaLzE2YMD44PA/132, createdBy=49f71976501, createdName=Doctoryangbai, createdTime=Fri Jan 07 13:00:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081506, encodeId=1951108150609, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d416410886, createdName=ms6000000788455640, createdTime=Sat Dec 18 11:25:33 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2022-09-18 ms6000000101327915

    紧跟国际发展

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1778672, encodeId=b1bd1e786722d, content=紧跟国际发展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2c65414596, createdName=ms6000000101327915, createdTime=Sun Sep 18 22:30:52 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206597, encodeId=faaf120659e04, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Mon Mar 28 11:34:15 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205894, encodeId=7277120589498, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210201/f9ebd76673be43709bf11ecf3e05d29a/4ceebf8544374796ac74a7ce757d6c8f.jpg, createdBy=28e01512509, createdName=40386, createdTime=Fri Mar 25 17:09:43 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181821, encodeId=c0aa11818219c, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXfB3bOYOsDt885AsrYWhiaRtRdPh9aZlXugm7XErBVXusv5fJLIKWTicmjSQcOibDiaLzE2YMD44PA/132, createdBy=49f71976501, createdName=Doctoryangbai, createdTime=Fri Jan 07 13:00:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081506, encodeId=1951108150609, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d416410886, createdName=ms6000000788455640, createdTime=Sat Dec 18 11:25:33 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2022-03-28 ms4000002026468787

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1778672, encodeId=b1bd1e786722d, content=紧跟国际发展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2c65414596, createdName=ms6000000101327915, createdTime=Sun Sep 18 22:30:52 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206597, encodeId=faaf120659e04, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Mon Mar 28 11:34:15 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205894, encodeId=7277120589498, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210201/f9ebd76673be43709bf11ecf3e05d29a/4ceebf8544374796ac74a7ce757d6c8f.jpg, createdBy=28e01512509, createdName=40386, createdTime=Fri Mar 25 17:09:43 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181821, encodeId=c0aa11818219c, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXfB3bOYOsDt885AsrYWhiaRtRdPh9aZlXugm7XErBVXusv5fJLIKWTicmjSQcOibDiaLzE2YMD44PA/132, createdBy=49f71976501, createdName=Doctoryangbai, createdTime=Fri Jan 07 13:00:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081506, encodeId=1951108150609, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d416410886, createdName=ms6000000788455640, createdTime=Sat Dec 18 11:25:33 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2022-03-25 40386

    受益匪浅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1778672, encodeId=b1bd1e786722d, content=紧跟国际发展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2c65414596, createdName=ms6000000101327915, createdTime=Sun Sep 18 22:30:52 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206597, encodeId=faaf120659e04, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Mon Mar 28 11:34:15 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205894, encodeId=7277120589498, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210201/f9ebd76673be43709bf11ecf3e05d29a/4ceebf8544374796ac74a7ce757d6c8f.jpg, createdBy=28e01512509, createdName=40386, createdTime=Fri Mar 25 17:09:43 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181821, encodeId=c0aa11818219c, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXfB3bOYOsDt885AsrYWhiaRtRdPh9aZlXugm7XErBVXusv5fJLIKWTicmjSQcOibDiaLzE2YMD44PA/132, createdBy=49f71976501, createdName=Doctoryangbai, createdTime=Fri Jan 07 13:00:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081506, encodeId=1951108150609, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d416410886, createdName=ms6000000788455640, createdTime=Sat Dec 18 11:25:33 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2022-01-07 Doctoryangbai

    获益匪浅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1778672, encodeId=b1bd1e786722d, content=紧跟国际发展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2c65414596, createdName=ms6000000101327915, createdTime=Sun Sep 18 22:30:52 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206597, encodeId=faaf120659e04, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ea35451111, createdName=ms4000002026468787, createdTime=Mon Mar 28 11:34:15 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205894, encodeId=7277120589498, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210201/f9ebd76673be43709bf11ecf3e05d29a/4ceebf8544374796ac74a7ce757d6c8f.jpg, createdBy=28e01512509, createdName=40386, createdTime=Fri Mar 25 17:09:43 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181821, encodeId=c0aa11818219c, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLyXfB3bOYOsDt885AsrYWhiaRtRdPh9aZlXugm7XErBVXusv5fJLIKWTicmjSQcOibDiaLzE2YMD44PA/132, createdBy=49f71976501, createdName=Doctoryangbai, createdTime=Fri Jan 07 13:00:13 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081506, encodeId=1951108150609, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d416410886, createdName=ms6000000788455640, createdTime=Sat Dec 18 11:25:33 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2021-12-18 ms6000000788455640

    学习

    0

以上为热门评论，梅斯医学App还有更多内容

拓展阅读

2021 ACC/AHA/SCAI指南：冠状动脉血运重建（执行概要）

美国心脏病学会基金会(ACCF,American College of Cardiology Foundation) · 2021-12-09

《2021 ACC/AHA/SCAI冠状动脉血运重建指南》解读

南京医科大学第一附属医院心内科 · 2022-08-19